Compare CVS Health Corp (CVS) vs Futu Holdings Ltd (FUTU) Price & Performance

CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.

The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.

Futu Holdings trades at $96.35, showing minimal daily movement. The stock faces a bearish technical signal with support near $95 and resistance at $97. Fundamentally, the company reported strong 2025 revenue of $22.85 billion and net income of $11.34 billion, with a robust net margin of 41.83%. However, recent earnings misses and a class action lawsuit alleging securities fraud have created significant headwinds.

The outlook is clouded by legal risks and inconsistent earnings performance, despite attractive valuation ratios like a P/E of 10.65. Analyst consensus remains cautiously optimistic with a majority 'Buy' rating, but investors must weigh solid profitability against substantial regulatory and litigation overhangs that could pressure the stock in the near term.